Key Highlights

  • Smith & Nephew plc (LSE:SN.) closed up 72.5p at 1,190p on 4 November 2026, one of the biggest risers on the FTSE 100.
  • Third-quarter Revenue rose 3.4% to $1,551 million on both an underlying and reported basis.
  • Full-year underlying revenue growth guidance was cut to around 3% because of continued weakness in US hips and knees.
  • The company confirmed it had approached Johnson & Johnson earlier in the year about a possible combination of DePuy Synthes and Smith+Nephew.

Why Smith & Nephew Is in Focus Today

Smith & Nephew plc (LSE:SN.) produced one of the most dramatic share price swings on the FTSE 100 on Wednesday, 4 November 2026. The medical technology group initially fell in early trade after it lowered its full-year revenue outlook in its third-quarter trading update. By the close, however, the shares had reversed sharply to finish 72.5p higher at 1,190p, a gain of roughly 6.5%, placing the stock among the top three risers in a market that climbed 1.8%.

The turnaround came as investors focused on a strategic disclosure tucked inside the update. Smith+Nephew confirmed that it had approached Johnson & Johnson earlier in the year about a possible combination between Johnson & Johnson's DePuy Synthes orthopaedics Business and Smith+Nephew. The company also said it continues to actively explore the full range of Options to deliver value for Stakeholders in its Orthopaedics division. For a business whose hip and knee Franchise has lagged larger rivals for years, the prospect of a transformational deal changed the tone of the day.

Third-Quarter Trading in Detail

For the quarter ended 26 September 2026, revenue rose to $1,551 million from $1,501 million a year earlier, an increase of 3.4% on both an underlying and reported basis, with the same number of trading days. US revenue rose about 3% to $812 million, other established markets grew about 2%, and emerging markets increased around 7% to $283 million.

Sports Medicine and ENT was again the bright spot, with double-digit growth in Sports Medicine Joint Repair. Advanced Wound Management improved, led by an acceleration in devices. Orthopaedics returned to growth, although US reconstruction remained under pressure in a softer market. More than half of the quarter's growth came from products launched in the past five years, with double-digit gains in products including CORI, REGENETEN, PICO and AETOS.

Guidance Revised Lower

Management now expects full-year underlying revenue growth of around 3%, reflecting its outlook for US hips and knees in the fourth quarter and broader market conditions. As a result of the lower revenue outlook, trading profit growth is now expected to be around 4%, to about $1.25 billion. The Acquisition of Integrity Orthopaedics is still expected to be marginally dilutive to trading profit in 2026, broadly neutral in 2027 and accretive from 2028.

This is the latest in a series of downgrades in 2026. In August the group had already cut its revenue growth target from around 6% to around 4% after a soft second quarter, so the latest move was not a complete surprise to the market.

Product Milestones

The update highlighted several regulatory milestones that could support a recovery in US knees. The cementless LANDMARK knee received 510(k) clearance, and the first US surgical cases have been completed. The company also completed first cases using its TESSA spatial surgery system for femoral repair of the anterior cruciate ligament and has submitted it for regulatory approval in tibial tunnel placement. Management said early customer feedback has been very positive.

The Strategic Angle

Activist investor Cevian holds more than 14% of the share register, adding pressure for value-creating action. A combination involving DePuy Synthes, which Johnson & Johnson has been preparing to separate, would create a far larger orthopaedics business with more scale in implants and robotics. No transaction has been agreed, and there is no certainty that one will follow, but the confirmation alone gives investors a clear catalyst to monitor.

Risks to Consider

The core risk remains execution in US hips and knees, where the company continues to lose ground. Reimbursement changes in advanced wound bioactives have also weighed on revenue this year. Any deal could involve complex regulatory reviews and integration challenges, while a failure to agree terms could see the shares give back some of Wednesday's gains.

What Investors Are Watching Next

Investors will look for any further statement on discussions with Johnson & Johnson or other strategic options for Orthopaedics. Fourth-quarter trading in US knees will be closely watched, along with the commercial ramp-up of cementless LANDMARK and TESSA. The full-year 2026 results, expected in February 2027, should bring guidance for 2027 and an update on Margin delivery. Wider MedTech sentiment and the Bank of England rate decision on 5 November may also influence trading in Smith & Nephew plc (LSE:SN.).